Eun Ji Lee

Eun Ji Lee

Auto-generated profile, based on publicly available information

Eun Ji Lee

Department of Biomedical Science institute, Graduated School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
ELEun Ji Lee
Eun Ji Lee
JKJae Hwan Kim
Jae Hwan Kim
YPYoungJoon Park
YoungJoon Park
MYMi Ran Yun
Mi Ran Yun
Purpose: MET amplification is a frequent mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC), and combined treatment with EGFR TKIs and MET TKIs has been explored as a strategy to overcome resistance. However, durable response is invariably limited by the emergence of acquired resistance. Here, we investigated the preclinical activity of REGN5093-M114, a novel antibody–drug conjugate targeting MET in MET-driven patient-derived models. Experimental Design: Patient-derived organoids, patient-derived cells, or ATCC cell lines were used to investigate the in vitro/in vivo activity of REGN5093-M114. Results: REGN5093-M114 exhibited significant antitumor efficacy compared with MET TKI or unconjugated METxMET biparatopic antibody (REGN5093). Regardless of MET gene copy number, MET-overexpressed TKI-naïve EGFR-mutant NSCLC cells responded to REGN5093-M114 treatment. Cell surface MET expression had the most predictive power in determining the efficacy of REGN5093-M114. REGN5093-M114 potently reduced tumor growth of EGFR-mutant NSCLC with PTEN loss or MET Y1230C mutation after progression on prior osimertinib and savolitinib treatment. Conclusions: Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
SLSun Min Lim
Sun Min Lim
SSStefanie S. Schalm
Stefanie S. Schalm
ELEun Ji Lee
Eun Ji Lee
SPSewon Park
Sewon Park
CCChiara Conti
Chiara Conti
BCByoung Chul Cho
Byoung Chul Cho
Introduction: Despite the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), most patients with non-small-cell lung cancer (NSCLC) eventually develop resistance to these agents. Notably, EGFR_C797S mutations confer resistance to the third-generation EGFR-TKI osimertinib and no approved post-osimertinib targeted pharmacology options are currently available. BLU-945 is a novel, reversible, and orally available next-generation EGFR-TKI that selectively targets EGFR-activating ( EGFRm) and resistance mutations (including EGFR_C797S) with nanomolar potency while sparing wild-type EGFR in vitro. Methods: In vitro activity of BLU-945 as a single agent and in combination with osimertinib was tested in engineered EGFR-mutant cell lines as well as patient-derived cells and patient-derived organoids. In vivo activity was evaluated in osimertinib-resistant patient-derived xenograft mouse models. Three patient cases from the global, first-in-human, phase I/II SYMPHONY trial (NCT04862780) demonstrating the clinical efficacy of BLU-945 were reported. Results: In vitro BLU-945 demonstrated inhibited cell viability and growth of EGFR-mutant/osimertinib-resistant cell lines. BLU-945 demonstrated in vivo tumor shrinkage in osimertinib-resistant models of NSCLC (osimertinib second line: EGFR_L858R/C797S and third line: EGFR_ex19del/T790M/C797S and L858R/T790M/C797S) both as monotherapy and in combination with osimertinib. BLU-945 also demonstrated tumor shrinkage in patients from the SYMPHONY trial. Conclusion: Our findings demonstrate the preclinical and early clinical activity of BLU-945 in EGFRm NSCLC progressing on previous EGFR-TKIs.

29 December 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
CSChun‐Bong Synn
Chun‐Bong Synn
SKSung Eun Kim
Sung Eun Kim
HLHee Kyu Lee
Hee Kyu Lee
MKMin‐Hwan Kim
Min‐Hwan Kim
JKJae Hwan Kim
Jae Hwan Kim
BCByoung Chul Cho
Byoung Chul Cho
Objectives: AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a small‐molecule inhibitor of AXL, alone and in combination with anti‐PD‐1 therapy.Methods: In vitro pAXL inhibition by SKI‐G‐801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti‐metastatic potential of SKI‐G‐801. Furthermore, SKI‐G‐801, anti‐PD‐1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.Results: SKI‐G‐801 robustly inhibited pAXL expression in various cell lines. SKI‐G‐801 alone or in combination with anti‐PD‐1 potently inhibited metastasis in B16F10 melanoma, CT26 colon and 4T1 breast models. SKI‐G‐801 inhibited the growth of B16F10 and 4T1 tumor‐bearing mice but not immune‐deficient mice. An antibody depletion assay revealed that CD8+ T cells significantly contributed to SKI‐G‐801‐mediated survival. Anti‐PD‐1 and combination group were observed the increased CD8+Ki67+ and effector T cells and M1 macrophage and decreased M2 macrophage, and granulocytic myeloid‐derived suppressor cell (G‐MDSC) compared to the control group. The neoadjuvant combination of SKI‐G‐801 and anti‐PD‐1 therapy achieved superior survival benefits by inducing more profound T‐cell responses in the 4T1 syngeneic mouse model.Conclusion: SKI‐G‐801 significantly suppressed tumor metastasis and growth by enhancing anti‐tumor immune responses. Our results suggest that SKI‐G‐801 has the potential to overcome anti‐PD‐1 therapy resistance and allow more patients to benefit from anti‐PD‐1 therapy.

8 February 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ELEun Ji Lee
Eun Ji Lee
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
JKJu Young Kim
Ju Young Kim
MKMin-Je Kim
Min-Je Kim
BCByoung Chul Cho
Byoung Chul Cho
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite the sustained clinical benefits achieved through optimal EGFR-TKI treatments, including the third-generation EGFR-TKI osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available postprogression on osimertinib. Here, we assessed the preclinical efficacy of BI-4732, a novel fourth-generation EGFR-TKI, using patient-derived preclinical models reflecting various clinical scenarios. Experimental Design: The antitumor activity of BI-4732 was evaluated using Ba/F3 cells and patient-derived cell/organoid/xenograft models with diverse EGFR mutations. Intracranial antitumor activity of BI-4732 was evaluated in a brain-metastasis mouse model. Results: We demonstrated the remarkable antitumor efficacy of BI-4732 as a single agent in various patient-derived models with EGFR_C797S-mediated osimertinib resistance. Moreover, BI-4732 exhibited activity comparable to osimertinib in inhibiting EGFR-activating (E19del and L858R) and T790M mutations. In a combination treatment strategy with osimertinib, BI-4732 exhibited a synergistic effect at significantly lower concentrations than those used in monotherapy. Importantly, BI-4732 displayed potent antitumor activity in an intracranial model, with low efflux at the blood–brain barrier. Conclusions: Our findings highlight the potential of BI-4732, a selective EGFR-TKI with high blood–brain barrier penetration, targeting a broad range of EGFR mutations, including C797S, warranting clinical development.

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
CSChun-Bong Synn
Chun-Bong Synn
DKDong Kwon Kim
Dong Kwon Kim
JKJae Hwan Kim
Jae Hwan Kim
YBYoungseon Byeon
Youngseon Byeon
YKYoung Seob Kim
Young Seob Kim
KPKyoung-Ho Pyo
Kyoung-Ho Pyo
Synn CB, et al. Yonsei Med J. 2022 Jan;63(1):42-55. https://doi.org/10.3349/ymj.2022.63.1.42

13 March 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
ELEun Ji Lee
Eun Ji Lee
JKJi Ae Ko
Ji Ae Ko
MKMin-Je Kim
Min-Je Kim
JCJae Seok Cho
Jae Seok Cho
JHJi-Youn Han
Ji-Youn Han
SLSun Min Lim
Sun Min Lim
Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) have revolutionized the treatment of non–small cell lung cancer (NSCLC) with activating EGFR mutations. However, acquired resistance—particularly the EGFR C797S mutation—remains a major clinical challenge. As no approved targeted therapies are available following disease progression on the third-generation EGFR-TKI osimertinib, this study aimed to evaluate JIN-A02, a novel fourth-generation EGFR-TKI, as a therapeutic strategy to overcome C797S-mediated resistance. Experimental Design: JIN-A02, a fourth-generation EGFR TKI, was evaluated for its antitumor efficacy and blood–brain barrier penetration in in vitro and in vivo models of NSCLC harboring EGFR C797S and T790M mutations. Results: JIN-A02 demonstrated potent antiproliferative activity in preclinical NSCLC models harboring EGFR C797S and T790M mutations, with superior inhibition of EGFR signaling compared with osimertinib. In both subcutaneous and orthotopic intracranial xenograft models, JIN-A02 elicited substantial tumor regression, indicating robust in vivo efficacy. The agent was well tolerated throughout the treatment period without notable toxicity. In line with preclinical data, early clinical trial data showed signs of efficacy, including three patients showing partial response. Conclusions: These findings highlight JIN-A02 as a promising therapeutic strategy to overcome C797S- and T790M-mediated resistance in EGFR-mutant NSCLC, including intracranial disease, and support its further clinical development.